BioNTech SE

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioNTech reports robust 2022 earnings, eyes growth in oncology and infectious diseases

BioNTech's strong financial performance in 2022 sets the stage for continued growth in 2023, with a focus on expanding its vaccine portfolio, advancing oncology programs, and navigating the evolving landscape of COVID-19. The company's strategic priorities align with market demands for infectious disease and oncology solutions, positioning BioNTech for future success and profitability.

BioNTech posts robust Q1 results, eyes growth in vaccines and oncology

BioNTech's Q1 2023 performance reflects strong financial results and promising developments in its vaccine and oncology programs.
While facing challenges such as seasonal trends and data constraints, the company is strategically positioned to leverage opportunities in commercial planning and therapeutic advancements.
With a focus on synergistic partnerships and innovative technologies, BioNTech aims to maintain its competitive edge in the biopharmaceutical industry.
The company's commitment to enhancing existing platforms and exploring new growth avenues underscores its resilience and adaptability in a dynamic market environment.

BioNTech reports mixed Q2 results, focuses on innovation and growth

BioNTech's Q2 2023 performance reflects a mix of strong revenue generation and financial challenges, emphasizing the importance of strategic focus.
The company's strengths lie in its innovative collaborations, pipeline advancements, and preparedness for market demands, despite facing financial losses.
Navigating challenges in financial sustainability, market competition, and stakeholder communication will be crucial for BioNTech's future growth and success.

BioNTech adjusts revenue guidance amidst vaccine demand challenges

BioNTech's Q3 2023 performance reflected revenue challenges from lower COVID-19 vaccine demand and write-downs, prompting revised revenue guidance.
Despite challenges, the company showcased strengths in vaccine development, oncology advancements, and strategic cost management initiatives.
Opportunities lie in shared R&D expenses, long-term growth prospects from combination vaccines, and maintaining financial strength during market transition.

BioNTech reports strong Q4 earnings, eyes diversified product expansion

BioNTech is strategically investing in expanding its product portfolio while navigating uncertainties in COVID-19 vaccine revenues. The company aims to transform into a multiproduct company by 2030, focusing on oncology and infectious diseases.

BioNTech advances oncology pipeline, eyes growth amid financial challenges

BioNTech is making significant strides in its oncology pipeline, aiming for multiple product launches by 2026 and focusing on cancer vaccines and mRNA treatments.
While facing financial losses and short-term profitability challenges, the company remains optimistic about its growth trajectory and revenue potential.
Strategic investments in technology platforms, commercial readiness, and partnerships position BioNTech for sustainable growth and value enhancement.
Balancing cost control, revenue generation, and clinical execution will be crucial for BioNTech to capitalize on opportunities and navigate challenges effectively.

BioNTech reports Q2 progress in oncology pipeline amid financial challenges

BioNTech's Q2 2024 earnings call highlighted progress in oncology and COVID-19 vaccines, with total revenues of EUR 129 million but a net loss of EUR 808 million. The company remains focused on advancing innovative therapies and expanding its global manufacturing capabilities.

BioNTech reports robust Q3 earnings, focuses on oncology pipeline

BioNTech's Q3 2024 performance was strong, driven by COVID-19 vaccines and oncology trials.
While facing revenue challenges in certain regions, the company remains focused on growth.
Opportunities lie in advancing oncology pipeline and demonstrating product potential.
Maintaining a strong cash position provides flexibility for future investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Moderna

Novavax

Concerns about the omicron variant as well as some good news are helping drive these vaccine stocks higher.

Why BioNTech, Moderna, and Novavax Stocks Are Jumping Today

AstraZeneca

Johnson & Johnson

Pfizer

It depends on what data the FDA requires.

How Quickly Could Vaccines Targeting the Omicron Variant Be Available?

It looks like the winners will keep winning.

What Does the Omicron Variant Mean for Vaccine Stocks?

Good news from the FDA wasn't enough to outweigh less positive updates this week.

Why BioNTech Stock Is Sinking Today

FDA authorizes the booster shot of Pfizer (PFE) and BioNTech's (BNTX) COVID-19 vaccine for 16- and 17-year olds.

Pfizer, BioNTech Booster Gets FDA Nod for 16- & 17-Year Olds

The CDC still needs to sign off on the boosters for teens.

FDA authorizes Pfizer boosters for 16- and 17-year-olds

The FDA has expanded the Emergency Use Authorization (EUA) of a booster dose of Pfizer Inc (NYSE: PFE) and BioNTech SE's (NASDAQ: BNTX) COVID-19 vaccine to include individuals 16 years of age and older.  The booster dose will be administered at least six months after completion of the primary series and is the same formulation and dosage strength as the primary series.

FDA Expands Emergency Use Of Pfizer/BioNTech's COVID-19 Booster To 16 Years & Older

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) of a booster dose of the Pfizer-BioNTech COVID-19 Vaccine to include individuals 16 years of age and older. The booster dose is to be administered at least six months after completion of the primary series and is the same formulation and dosage strength as the doses in the primary se

Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 16 Years and Older

The Food and Drug Administration said 16- and 17-year-olds can now get booster doses of BioNTech SE BNTX, -0.22% and Pfizer Inc.'s PFE, +2.41% COVID-19 vaccine. BioNTech's stock was down 0.1% in trading on Thursday, while Pfizer shares gained 1.7%.

FDA authorizes BioNTech, Pfizer's COVID-19 booster for 16- and 17-year-olds

The FDA authorized the Pfizer COVID-19 booster shot for all adults in the United States in November.

The FDA says 16- and 17-year-olds can now get a Pfizer vaccine booster shot

The FDA authorization comes a day after Pfizer released lab data indicating that booster shots provide high levels of protection against the omicron variant.

FDA expands eligibility for Pfizer Covid booster shots to 16- and 17-year-olds

Investors were weighing a good news/bad news update about the coronavirus vaccine co-developed by the biotech.

Why BioNTech Stock Slipped on Wednesday

Good news about a booster dose with the omicron variant could be bad news for the biotech's future sales.

Why BioNTech Stock Is Sliding Today

Early lab data released Wednesday suggests a booster shot of the Pfizer-BioNTech vaccine is necessary to ensure protection against omicron, rather than just two doses.

Will Omicron Change What ‘Fully Vaccinated' Means? BioNTech CEO Says Full Vaccine Regimen Against Variant Is 3 Doses, Not 2.

The stock price of BioNTech SE (NASDAQ: BNTX) increased by over 4% pre-market today. This is why it happened.

BioNTech Stock (BNTX): Why The Price Increased Today

Yields for U.S. government debt on Wednesday were trading mixed as investors digested news suggesting the omicron variant of coronavirus that causes COVID-19 may not impact the economy as much as feared.

Bond Report: U.S. Treasury yields steady after Pfizer/BioNTech omicron report

A small study in South Africa shows that the omicron variant can partially evade protection from two doses of Pfizer Inc (NYSE: PFE) / BioNTech SE's (NASDAQ: BNTX) COVID-19 vaccine. But the study did show that blood from people who had received two doses of the vaccine and had a prior infection were primarily able to neutralize the variant, thus suggesting booster doses of the vaccine could help to fend off the infection.

Pfizer/BioNTech COVID-19 Shot Provides Partial Protection Against Omicron, Study Shows

A booster shot of the vaccine increases antibody protection 25-fold compared with the initial two-dose series, according to a preliminary lab study.

Pfizer-BioNTech say booster dose provides high level of protection against omicron variant

Pfizer Inc. PFE, +0.47% and BioNTech SE BNTX, +8.17% said results from an "initial laboratory study" showed that their COVID-19 vaccine neutralized the omicron variant of the coronavirus after three doses, or the full two-dose regimen plus a booster shot. The drug makers said those who received just two does of the vaccine showed, on average, a more than 25-fold reduction in neutralization against the omicron variant.

Pfizer, BioNTech say initial lab study showed 3 doses of COVID-19 vaccine neutralized omicron variant

MAINZ, Germany, December 8, 2021 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will hold a digital press conference on Wednesday, December 8, 2021, to present the results from initial laboratory studies which started about two weeks ago. The studies aimed to investigate the effects of the Omicron variant on COVID-19 vaccine-induced immune responses. The press conference will solely be held in a virtual format and will be conducted in English.

BioNTech to Hold Digital Press Conference to Provide an Update on Omicron Variant

NEW YORK and MAINZ, Germany, December 8, 2021 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced results from an initial laboratory study demonstrating that serum antibodies induced by the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) neutralize the SARS-CoV-2 Omicron variant after three doses. Sera obtained from vaccinees one month after receiving the booster vaccination (third dose of BNT162b2 vaccine) neutralized the Omicron variant to levels that are comparable to those observed for the wild-type SARS-CoV-2 spike protein after two doses.

Pfizer and BioNTech Provide Update on Omicron Variant

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced results from an initial laboratory study demonstrating that serum antibodies induced by the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) neutralize the SARS-CoV-2 Omicron variant after three doses. Sera obtained from vaccinees one month after receiving the booster vaccination (third dose of BNT162b2 vaccine) neutralized the Omicron variant to levels that are comparable to those obse

Pfizer and BioNTech Provide Update on Omicron Variant.

Merck

Stocks of Moderna (MRNA), BioNTech (BNTX), Novavax (NVAX) and Pfizer (PFE) decline as data suggests that Omicron variant may cause less severe cases of COVID-19.

Vaccine Stocks Down as Omicron May Not Be Too Severe

The stock price of BioNTech SE (NASDAQ: BNTX) fell by 18.67% today. This is why it happened.

BioNTech Stock (BNTX): Why The Price Dropped Today

Dr. Fauci has implied that the omicron variant may not be as severe as feared. Vaccine stocks have taken a hit as a result.

News for BioNTech SE Stock (BNTX)